JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB120165

1400W, iNOS inhibitor

Be the first to review this product! Submit a review

|

(6 Publications)

MW 250.17 Da, Purity >97%. Selective iNOS inhibitor, 5000-fold selective over eNOS (Kd values are ≤7 nM, 2 μM and 50 μM at human iNOS, nNOS and eNOS, respectively).

View Alternative Names

ACEE, ACES_HUMAN, ACLS, AI838772, AIS, ANDR_HUMAN, AR, AR8, ARACHE, AW493413, Acetylcholinesterase, Androgen nuclear receptor variant 2, Androgen receptor, Androgen receptor (dihydrotestosterone receptor; testicular feminization; spinal and bulbar muscular atrophy; Kennedy disease), Antigen NY-CO-13, Apoptosis related acetylcholinesterase, Atherosclerosis, susceptibility to, included, BCC7, BNOS, CAR, CAR BETA, CARA, Car 1, Cellular tumor antigen p53, Constitutive NOS, Constitutive activator of retinoid response, Constitutive active response, Constitutive androstane receptor, DHTR, DKFZp686N23123, DNA binding protein, Dihydro testosterone receptor, Dihydrotestosterone receptor (DHTR), ER, ER-alpha, ER-beta, ERR a, ERR-alpha, ERR1 protein, ERR1_HUMAN, ER[a], ER[b], ESR, ESR B, ESR BETA, ESR1_HUMAN, ESRA, ESRL 1, ESRR A, ESTR B, Era, Erb, Erb2, Estr, Estra, Estradiol Receptor alpha, Estradiol Receptor beta, Estradiol receptor, Estrogen Receptor 1, Estrogen Receptor 2, Estrogen receptor, Estrogen receptor 1 (alpha), Estrogen receptor 2 (ER beta), Estrogen receptor 2 ER beta, Estrogen receptor alpha, Estrogen receptor beta 4, Estrogen receptor related 1, Estrogen receptor-like 1, Estrogen resistance, included, Estrogen-related receptor alpha, Estrra, FLJ11090, FLJ92943, GCPS, GLI Kruppel family member GLI 3, GLI Kruppel family member GLI3 (Greig cephalopolysyndactyly syndrome), GLI family zinc finger 3, GLI3 C-terminally truncated form, GLI3 form of 190 kDa, GLI3 form of 83 kDa, GLI3 full length protein, GLI3-190, GLI3-83, GLI3FL, GLI3_HUMAN, Glioma associated oncogene family zinc finger 3, HDL cholesterol, augmented response of, to hormone replacement, included, HEP-NOS, HUMARA, HYSP1, Hepatocyte NOS, IHPS 1, Inducible NO synthase, Inducible NOS, Inducible nitric oxide synthase, KD, Kennedy disease (KD), LFS1, MAC NOS, MB67, MGC104252, MGC112732, MGC97144, Macrophage NOS, Mutant tumor protein 53, Myocardial infarction, susceptibility to, included, N-ACHE, N-NOS, NC-NOS, NOS, NOS type I, NOS type II, NOS2A, NOS2A, Inducible, Hepatocyte, NOS2_HUMAN, NR1I3_HUMAN, NR3A1, NR3A2, NR3B1, NR3C4, Neuronal NOS, Nitric oxide synthase, Nitric oxide synthase 1, Nitric oxide synthase 1 neuronal, Nitric oxide synthase 2 inducible, Nitric oxide synthase 2 inducible macrophage, Nitric oxide synthase brain, Nitric oxide synthase inducible, Nos II, Nuclear receptor subfamily 1 group I member 3, Nuclear receptor subfamily 3 group A member 1, Nuclear receptor subfamily 3 group A member 2, Nuclear receptor subfamily 3 group B member 1, Nuclear receptor subfamily 3 group C member 4, Nuclear receptor subfamily 3 group C member 4 (NR3C4), OTTHUMP00000017718, OTTHUMP00000017719, Oncogene GLI3, Orphan nuclear receptor MB67, Orphan nuclear receptor NR1I3, P53_HUMAN, PAP A, PAPB, PPD IV, Peptidyl-cysteine S-nitrosylase NOS2, Phosphoprotein p53, RNESTROR, RP24-311F12.2, SBMA, SCAN1, SMAX1, Spinal and bulbar muscular atrophy, Spinal and bulbar muscular atrophy (SBMA), Steroid hormone receptor ERR1, TFM, TRP53, TYDP, TYDP1_HUMAN, Testicular Feminization (TFM), Tp53, Transcriptional activator GLI3, Transcriptional repressor GLI3R, Transformation related protein 53, Tumor protein 53, Tumor protein p53, Tumor suppressor p53, Tyr-DNA phosphodiesterase 1, Tyrosyl-DNA phosphodiesterase 1, YT, YT blood group, Zinc finger protein GLI 3, androgen receptor splice variant 4b, constitutive active receptor, constitutive androstane nuclear receptor variant 2, constitutive androstane nuclear receptor variant 3, constitutive androstane nuclear receptor variant 4, constitutive androstane nuclear receptor variant 5, estrogen receptor related receptor alpha, hERR1, iNOS, inducible, neuronal Nitric Oxide Synthase, nitric oxide synthase 2A (inducible, hepatocytes), nitric oxide synthase, macrophage, orphan nuclear hormone receptor, p53 tumor suppressor, tumor antigen p55

1 Images
Chemical Structure - 1400W, iNOS inhibitor (AB120165)
  • Chemical Structure

Lab

Chemical Structure - 1400W, iNOS inhibitor (AB120165)

2D chemical structure image of ab120165, 1400W, iNOS inhibitor

Key facts

CAS number

214358-33-5

Purity

>97%

Form

Solid

form

Molecular weight

250.17 Da

Molecular formula

C<sub>1</sub><sub>0</sub>H<sub>1</sub><sub>7</sub>Cl<sub>2</sub>N<sub>3</sub>

PubChem

2733515

Nature

Synthetic

Solubility

Soluble in water to 100 mM

Biochemical name

1400W dihydrochloride

Biological description

Selective iNOS inhibitor, 5000-fold selective over eNOS (Kd values are ≤7 nM, 2 μM and 50 μM at human iNOS, nNOS and eNOS, respectively).

Canonical smiles

CC(=NCC1=CC=CC(=C1)CN)N.Cl.Cl

InChi

InChI=1S/C10H15N3.2ClH/c1-8(12)13-7-10-4-2-3-9(5-10)6-11;;/h2-5H,6-7,11H2,1H3,(H2,12,13);2*1H

InChiKey

WDJHSQZCZGPGAA-UHFFFAOYSA-N

IUPAC Name

N'-[[3-(aminomethyl)phenyl]methyl]ethanimidamide;dihydrochloride

Properties and storage information

Shipped at conditions
Ambient - Can Ship with Ice
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
+4°C
Storage information
Store under desiccating conditions|The product can be stored for up to 12 months

Product protocols

Publications (6)

Recent publications for all applications. Explore the full list and refine your search

The Journal of clinical investigation 134: PubMed39352757

2024

Neuropilin-2-expressing breast cancer cells mitigate radiation-induced oxidative stress through nitric oxide signaling.

Applications

Unspecified application

Species

Unspecified reactive species

Ayush Kumar,Hira Lal Goel,Christi A Silva,Tao Wang,Yansong Geng,Mengdie Wang,Shivam Goel,Kai Hu,Rui Li,Lihua J Zhu,Jennifer L Clark,Lindsay M Ferreira,Michael A Brehm,Thomas J FitzGerald,Arthur M Mercurio

Frontiers in pharmacology 13:861183 PubMed35910349

2022

An Inducible Nitric Oxide Synthase Dimerization Inhibitor Prevents the Progression of Osteoarthritis.

Applications

Unspecified application

Species

Unspecified reactive species

Shang Xian Bo,Wang Yan Jie,Cai De Chao,Ma Sai,Wang Zhe,Zhu Ya Kun,Guo Hui Hui,Wang Chen,Ma Xiao,Hu Zhong Yao,Yu Hao Ran,Zhang Ji Sen,Cheng Wen Dan

Immunity 55:423-441.e9 PubMed35139355

2022

Interferon-γ primes macrophages for pathogen ligand-induced killing via a caspase-8 and mitochondrial cell death pathway.

Applications

Unspecified application

Species

Unspecified reactive species

Daniel S Simpson,Jiyi Pang,Ashley Weir,Isabella Y Kong,Melanie Fritsch,Maryam Rashidi,James P Cooney,Kathryn C Davidson,Mary Speir,Tirta M Djajawi,Sebastian Hughes,Liana Mackiewicz,Merle Dayton,Holly Anderton,Marcel Doerflinger,Yexuan Deng,Allan Shuai Huang,Stephanie A Conos,Hazel Tye,Seong H Chow,Arfatur Rahman,Raymond S Norton,Thomas Naderer,Sandra E Nicholson,Gaetan Burgio,Si Ming Man,Joanna R Groom,Marco J Herold,Edwin D Hawkins,Kate E Lawlor,Andreas Strasser,John Silke,Marc Pellegrini,Hamid Kashkar,Rebecca Feltham,James E Vince

Andrologia 53:e14138 PubMed34137064

2021

Inhibition of inducible nitric oxide synthase improved erectile dysfunction in rats with type 1 diabetes.

Applications

Unspecified application

Species

Unspecified reactive species

Li Liu,Xiao Wang,Kang Liu,Jiaqi Kang,Shangren Wang,Yuxuan Song,Kechong Zhou,Lu Yi,Xiaoqiang Liu

Redox biology 43:101989 PubMed33940548

2021

Lysosomal nitric oxide determines transition from autophagy to ferroptosis after exposure to plasma-activated Ringer's lactate.

Applications

Unspecified application

Species

Unspecified reactive species

Li Jiang,Hao Zheng,Qinying Lyu,Shotaro Hayashi,Kotaro Sato,Yoshitaka Sekido,Kae Nakamura,Hiromasa Tanaka,Kenji Ishikawa,Hiroaki Kajiyama,Masaaki Mizuno,Masaru Hori,Shinya Toyokuni

Biochemistry and biophysics reports 2:153-159 PubMed29124157

2015

The constituents of licorice () differentially suppress nitric oxide production in interleukin-1β-treated hepatocytes.

Applications

Unspecified application

Species

Unspecified reactive species

Ryunosuke Tanemoto,Tetsuya Okuyama,Hirotaka Matsuo,Tadayoshi Okumura,Yukinobu Ikeya,Mikio Nishizawa
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com